{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:51:19Z","timestamp":1791885079742,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Pseudobulbar affect is a very distressing and underdiagnosed neuropsychiatric disorder that causes contextually inappropriate episodes of laughing and crying and general emotional incontinence. Although many proposed etiologies exist, the most widely accepted theory espouses the disruption of a corticopontine\u2013cerebellar circuit that governs the modulation of emotional response. Pseudobulbar affect is commonly diagnosed secondary to primary neurological disorders such as amyotrophic lateral sclerosis, multiple sclerosis, and traumatic brain injury. Traditional pharmacological treatment of pseudobulbar affect is largely comprised of antidepressant therapy, including tricyclic antidepressants such as amitriptyline and selective serotonin reuptake inhibitors such as fluvoxamine. However, neither of these medication classes has been studied for the treatment of pseudobulbar affect in controlled trials, and their utility remains questionable.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>We describe a case of a 62-year-old Caucasian man with history of traumatic brain injury, ischemic brainstem stroke, and depression who developed intractable pseudobulbar affect. This patient\u2019s intensely distressing symptoms were not alleviated by amitriptyline. However, after being placed on fixed-dose 20\u2009mg\/10\u2009mg dextromethorphan\/quinidine (Nuedexta), our patient experienced complete resolution of his symptoms. He has experienced no deleterious side effects.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This case provides anecdotal evidence for the efficacy of dextromethorphan\/quinidine in the treatment of pseudobulbar affect with remarkably swift and complete cessation of symptoms. As a secondary point, it is worth noting that our\u00a0patient had experienced two devastating neurological traumas, both in anatomical areas that have been implicated in the corticopontine\u2013cerebellar circuit thought to be responsible for pseudobulbar affect. However, only the second trauma, an acute left pontine infarction, produced symptoms of emotional disinhibition. The authors hope that reporting this case will provide both context for physicians managing this condition and hope for patients with this socially and psychiatrically damaging disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-02525-3","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:05:16Z","timestamp":1607040316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6466-4020","authenticated-orcid":false,"given":"Fletcher Graham","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diep","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"2525_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/ana.21056","volume":"61","author":"HJ Rosen","year":"2007","unstructured":"Rosen HJ, Cummings J. A real reason for patients with pseudobulbar affect to smile. Ann Neurol. 2007;61:92\u20136.","journal-title":"Ann Neurol"},{"key":"2525_CR2","doi-asserted-by":"publisher","unstructured":"Miller A, Pratt H, Schiffer RB. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother. 2011;11(7):295 1077\u201388. https:\/\/doi.org\/10.1586\/ern.11.68.","DOI":"10.1586\/ern.11.68"},{"key":"2525_CR3","first-page":"343","volume-title":"Handbook of clinical neurology","author":"K Poeck","year":"1969","unstructured":"Poeck K. Pathophysiology of emotional disorders associated with brain damage. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: North Holland; 1969. p. 343\u201367."},{"issue":"S6","key":"2525_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852900026614","volume":"11","author":"JL Cummings","year":"2006","unstructured":"Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr. 2006;11(S6):1\u20137.","journal-title":"CNS Spectr"},{"issue":"6","key":"2525_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1191\/1352458504ms1106oa","volume":"10","author":"RA Smith","year":"2004","unstructured":"Smith RA, Berg JE, Pope LE, Callahan JD, Wynn D, Thisted RA. Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler. 2004;10(6):679\u201385.","journal-title":"Mult Scler"},{"key":"2525_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12325-011-0031-3","volume":"28","author":"SS Work","year":"2011","unstructured":"Work SS, Colamonico JA, Bradley WG, et al. Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Adv Ther. 2011;28:586\u2013601.","journal-title":"Adv Ther"},{"key":"2525_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","volume":"164","author":"CP Taylor","year":"2016","unstructured":"Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan\/quinidine (Nuedexta\u00ae) clinical use. Pharmacol Ther. 2016;164:170\u201382.","journal-title":"Pharmacol Ther"},{"key":"2525_CR8","unstructured":"Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) oral capsules, prescribing information. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; Oct 2010. Revised August 2011. https:\/\/www.nuedexta.com\/sites\/default\/files\/pdfs\/Prescribing_Information.pdf.\u00a0Accessed 27 May 2020."},{"key":"2525_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.01.016","volume":"159","author":"L Nguyen","year":"2016","unstructured":"Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1\u201322.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2525_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.14802\/jmd.18051","volume":"12","author":"M Hakimi","year":"2019","unstructured":"Hakimi M, Maurer CW. Pseudobulbar affect in parkinsonian disorders: a review. J Mov Disord. 2019;12(1):14\u201321.","journal-title":"J Mov Disord"},{"key":"2525_CR11","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1212\/01.WNL.0000142042.50528.2F","volume":"63","author":"BR Brooks","year":"2004","unstructured":"Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan\/quinidine: a randomized trial. Neurology. 2004;63:1364\u201370.","journal-title":"Neurology"},{"key":"2525_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.20828","volume":"59","author":"HS Panitch","year":"2006","unstructured":"Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan\/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59:780\u20137.","journal-title":"Ann Neurol"},{"key":"2525_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/ana.22093","volume":"68","author":"EP Pioro","year":"2010","unstructured":"Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693\u2013702.","journal-title":"Ann Neurol"},{"issue":"10","key":"2525_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.pmrj.2018.02.010","volume":"10","author":"FM Hammond","year":"2018","unstructured":"Hammond FM, Sauve W, Ledon F, Davis C, Formella AE. Safety, tolerability, and effectiveness of dextromethorphan\/quinidine for pseudobulbar affect among study participants with traumatic brain injury: results from the PRISM-II open label study. PM R. 2018;10(10):993\u20131003.","journal-title":"PM R"},{"issue":"1-2","key":"2525_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jns.2008.04.017","volume":"271","author":"G Haiman","year":"2008","unstructured":"Haiman G, Pratt H, Miller A. Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect. J Neurol Sci. 2008;271(1-2):137\u201347.","journal-title":"J Neurol Sci"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-020-02525-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:47:47Z","timestamp":1607042867000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02525-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2525"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02525-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"20 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}